Drug Profile
Research programme: cancer therapeutics - Emiliem
Alternative Names: EM 100; EM 101; EM 300; EM 370; EM 400; Molecular targeted therapeutics - EmiliemLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Emiliem; National Institutes of Health (USA)
- Developer Emiliem
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Angiogenesis inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 22 Nov 2008 Applied Biosystems Inc has merged with Invitrogen Corporation to form Life Technologies Corporation
- 24 Apr 2008 Emiliem receives a worldwide license for a series of compounds from the NIH